Core Scientific stock rating reiterated at Market Outperform by JMP

Core Scientific (CORZ) is facing significant shareholder opposition, led by its largest active investor Two Seas Capital, regarding its proposed $9 billion all-stock acquisition by CoreWeave, with dissenters citing undervaluation and economic risks. While Core Scientific is strategically pivoting towards high-performance computing and anticipates profitability this year, the acquisition's current terms are seen by firms like JMP Securities as heavily favoring CoreWeave, creating substantial uncertainty for the deal's expected Q4 2025 completion. This contentious situation has resulted in mixed analyst ratings, highlighting the complex and divergent outlooks for both companies.

Analysis

Core Scientific (CORZ) is at a critical juncture, defined by a contentious all-stock acquisition proposal from CoreWeave and a fundamental business pivot towards high-performance computing (HPC). The proposed $9 billion transaction faces significant opposition from Core Scientific's largest active shareholder, Two Seas Capital, which argues the deal undervalues the company and introduces substantial economic risk. This view is echoed by JMP Securities, which noted the 0.1235 exchange ratio represents an "unambiguous win for CoreWeave shareholders," implying unfavorable terms for CORZ investors. This has created a fractured analyst landscape; JMP downgraded CORZ to Market Perform citing limited upside from the deal, while Bernstein reiterated an Outperform rating with a $17.00 price target. Fundamentally, Core Scientific's transition to HPC is reportedly on track, and despite being currently unprofitable, the company is forecasted by analysts to achieve profitability this year with earnings of $0.38 per share. The ultimate success and value of the acquisition, targeted for a Q4 2025 close, remain highly uncertain and contingent upon potential renegotiations and the stock performance of CoreWeave.

Key Decisions for Investors

• Investors should recognize the significant event-driven risk tied to the CoreWeave acquisition, as strong shareholder opposition makes the deal's completion by Q4 2025 highly uncertain and subject to potential revision.
• The current valuation dispute presents a potential special situation opportunity, where returns could be generated from either a renegotiated, higher acquisition price for CORZ or a deal failure that allows the market to re-evaluate the company on its standalone HPC strategy.
• Monitor CoreWeave's stock performance and communications from key shareholders like Two Seas Capital, as these are the primary catalysts that will likely influence the final transaction terms and value for CORZ investors.
• Evaluate Core Scientific based on its operational execution in the HPC sector and its progress toward forecasted profitability, as this fundamental value serves as a critical baseline for assessing the adequacy of the current or any future acquisition offers.